Predictive value of SCC-Ag, CYFRA 21-1 and selected acute phase proteins in radiotherapy of pharyngeal and laryngeal cancer. A preliminary report

Neoplasma

Volumn 51, Issue 2, 2004, Pages 103-109

  Kulpa, J ^a   Stasik, Z ^a   Skolyszewski J ^a   Wojcik E ^a   Rychlik, U ^a   Pudelek K ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Acute phase proteins; CYFRA 21 1; Pharynx and larynx cancer; Prognostic value; SCC Ag

Indexed keywords

ACUTE PHASE PROTEIN; ALBUMIN; ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; CERULOPLASMIN; CYTOKERATIN 19 FRAGMENT; OROSOMUCOID; PREALBUMIN; SQUAMOUS CELL CARCINOMA ANTIGEN; TRANSFERRIN; TUMOR MARKER;

ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; LARYNX CANCER; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PHARYNX CANCER; PROGNOSIS;

EID: 2342598235     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. BANAL A, HACENE K, BERTHELOT-RUFF E, MAHE E, FONTANA X, PICHON MF. Comparison of Cyfra 21-1 and SCC assays in head and neck tumors. Tumor Biol 2001; 22: 27-35.
2. BONGERS V, BRAAKHUIS BJM, SNOW GB. Circulating fragments of cytokeratin 19 in patients with head and neck squamous cell carcinoma. Clin Otolaryngol 1995; 20: 479-482.
3. DOWECK I, BARAK M, GREENBERG E. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of the head and neck and its role in early detection of recurrent disease. Br J Cancer 2000; 83: 1696-1701.
4. FICHBACH N, MEYER T, BARTHEL K. Squamous cell carcinoma antigen in the diagnosis and treatment follow-up of oral and facial squamous cell carcinoma. Cancer 1990; 65: 1321-1324.
5. GALLO O, GORI AM, ATTANASIO M, MARTINI F, GIUSTI B et al. Interleukin-6 and acute-phase proteins in head and neck cancer. Eur Arch Otorhinolaryngol 1995; 252: 159-162.
6. GORANSSON J, JONSSON S, LASSON A. Pre-operative plasma levels of C-reactive protein, albumin and various plasma protease inhibitors for the pre-operative assessment of operability and recurrence in cancer surgery. Eur J Surg Oncol 1996; 22: 607-617.
7. HANNISDAL E, TVEIT KV, THEODORSEN L, HOST H. Host markers and prognosis in recurrent rectal carcinomas treated with radiotherapy. Acta Oncologica 1994; 33: 415-421.
8. JAMES WPT, HAY AM. Albumin metabolism: Effect of the nutritional state and the dietary protein intake. J Clin Invest 1968; 47: 1958-1971.
9. KULPA J, WÓJCIK E, REINFUSS M, KOLODZIEJSKI L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002; 48(11): 1931-1937.
10. LARA PC, CUYAS JM. The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer. Cancer 1995; 76: 758-764.
11. LJUNGBERG B, GRANKVIST K, RASMUSON T. Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer 1995; 76: 1435-1439.
12. MOLINA R, FILELLA X, TORRES MD, BALLESTA AM, MENGUAL P et al. SCC antigen measured in malignant and non-malignant diseases. Clin Chem 1990; 36: 251-254.
13. MOLINA R, TORRES MD, MORAGAS M, FILELLA X, JO J et al. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC. Anticancer Res 1995; 15: 479-484.
14. MULLER T, MARSHALL RJ, COOPER EH, WATSON DA, WALKER DA, MEARNS AJ.The role of serum tumour markers to aid the selection of lung cancer patients for surgery and the assessment of prognosis. Eur J Cancer Clin Oncol 1985; 21: 1461-1466.
15. NAKASHIMA T, TANAKA M, OKAMURA S-I. Survey of immunosuppressive acidic protein and other immunological parameters in head and neck cancer patients. J Laryngol Otol 1991; 105: 939-945.
16. OGAWA T, TSURUSAKO Y, KIMURA N, NISHIOKA S, AKAGI H et al. Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck. Acta Otolaryngol 1999; Suppl 540: 72-76.
17. OVERGAARD J, HANSEN HS, JORGENSEN K, HANSEN MH. Primary radiotherapy of larynx and pharynx carcinoma-an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys 1986; 12(4): 515-521.
18. PINILLA JC, HAYES P, LAVERTY W, ARNOLD C, LAXDAL V. The C-reactive protein to prealbumin ratio correlate with the severity of multiple organ dysfunction. Surgery 1998; 124: 799-806.
19. PRADIER O, HILLE A, SCHMIBERGER H, HESS CF. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1. Cancer/Radiother 2002; 6: 15-21.
20. PUJOL JL, GRENIER J, DAURES JP, DAVER A, PUJOL H, MICHEL FB. Serum fragment of cytokeratin 19 measured by Cyfra 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993; 53: 61-66.
21. SNYDER S, ASHWELL G. Quantitation of specific serum glycoprotein in malignancy. Clin Chimica 1971; 34: 449-455.
22. SPITZ MR. Epidemiology and risk factors for head and neck cancer. Semin Oncol 1994; 21(3): 281-288.
23. STIEBER P, HASHOLZNER U, BODENMULLER H, NAGEL D, SUNDER-LASSMANN L et al. Cyfra 21-1 a new marker in lung cancer. Cancer 1993; 72: 707-713.
24. VELTRI RW, RODMAN SM, MAXIM PE, BASELER MW, SPRINKLE PM. Immune complexes, serum proteins, cell-mediated immunity, and immune regulation in patients with squamous cell carcinoma of the head and neck. Cancer 1986; 57: 2295-2308.
25. WALTHER EK, DAHLMANN N, GORGULLA HT. Tumour markers in the diagnosis and follow-up of head and neck cancer: role of CEA, CA 19-9, SCC, TK, and DTTPASE. Head & Neck 1993; 15: 230-235.
26. WOLF GT, CHRIETIEN PB, ELIES EG, MAKUCH RW, BASKIES AM et al. Serum glycoproteins in head and neck squamous carcinoma. Correlations with tumor extent, clinical tumor stage and T-cell levels during chemotherapy. Am J Surg 1979; 138: 489-500.